{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T17:18:55Z","timestamp":1787678335346,"version":"build-2784847793"},"reference-count":17,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:00:00Z","timestamp":1786579200000},"content-version":"vor","delay-in-days":12,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thrombosisresearch.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.thromres.2026.109795","type":"journal-article","created":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:34:05Z","timestamp":1786322045000},"page":"109795","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Long-term analytical performance of apixaban measurements based on external quality assessment data"],"prefix":"10.1016","volume":"264","author":[{"given":"Bob","family":"Smit","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piet","family":"Meijer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"An","family":"Stroobants","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"13","key":"10.1016\/j.thromres.2026.109795_bb0005","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.017559","article-title":"Direct oral anticoagulant use: a practical guide to common clinical challenges","volume":"9","author":"Chen","year":"2020","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.thromres.2026.109795_bb0010","article-title":"European heart rhythm association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation","volume":"23","author":"Steffel","year":"2021","journal-title":"EP Europace."},{"issue":"13","key":"10.1016\/j.thromres.2026.109795_bb0015","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11133788","article-title":"Effectiveness and safety of apixaban in over 3.9 million people with atrial fibrillation: a systematic review and meta-analysis","volume":"11","author":"Buckley","year":"2022","journal-title":"J. Clin. Med."},{"issue":"11","key":"10.1016\/j.thromres.2026.109795_bb0020","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.thromres.2026.109795_bb0025","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1055\/a-1450-8178","article-title":"2021 update of the International Council for Standardization in Haematology recommendations for laboratory measurement of direct oral anticoagulants","volume":"121","author":"Douxfils","year":"2021","journal-title":"Thromb. Haemost."},{"issue":"2","key":"10.1016\/j.thromres.2026.109795_bb0030","doi-asserted-by":"crossref","DOI":"10.1111\/jth.13912","article-title":"Laboratory testing in patients treated with direct oral anticoagulants: a practical guide for clinicians","volume":"16","author":"Douxfils","year":"2018","journal-title":"J. Thromb. Haemost."},{"issue":"7","key":"10.1016\/j.thromres.2026.109795_bb0035","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1093\/clinchem\/48.7.1011","article-title":"Long-term analytical performance of hemostasis field methods as assessed by evaluation of the results of an external quality assessment program for antithrombin","volume":"48","author":"Meijer","year":"2002","journal-title":"Clin. Chem."},{"key":"10.1016\/j.thromres.2026.109795_bb0040","doi-asserted-by":"crossref","first-page":"184","DOI":"10.11613\/BM.2010.023","article-title":"Quality in coagulation and haemostasis testing","volume":"20","author":"Bonar","year":"2010","journal-title":"Biochem. Med."},{"key":"10.1016\/j.thromres.2026.109795_bb0045","doi-asserted-by":"crossref","DOI":"10.21037\/aob.2019.07.03","article-title":"Assessing quality in the specialized hemostasis laboratory: review and critique of external quality assurance (EQA) programs in the US","volume":"4","author":"Gosselin","year":"2019","journal-title":"Ann. Blood"},{"issue":"3","key":"10.1016\/j.thromres.2026.109795_bb0050","first-page":"460","article-title":"International external quality assessment for measurements of direct oral anticoagulants: results and recommendations","volume":"188","author":"Hollestelle","year":"2019"},{"issue":"3","key":"10.1016\/j.thromres.2026.109795_bb0055","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1097\/FTD.0000000000000509","article-title":"Quantification of apixaban, dabigatran, edoxaban, and rivaroxaban in human serum by UHPLC\u2013MS\/MS\u2014method development, validation, and application","volume":"40","author":"Lindahl","year":"2018","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.thromres.2026.109795_bb0060","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1111\/jth.13949","article-title":"Interlaboratory variation in the measurement of direct oral anticoagulants: results from the external quality assessment scheme","volume":"16","author":"Tripodi","year":"2018","journal-title":"J. Thromb. Haemost."},{"issue":"4","key":"10.1016\/j.thromres.2026.109795_bb0065","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1111\/ijlh.14288","article-title":"Performance of direct oral anticoagulant (DOAC) testing by participants in an external quality assessment program","volume":"46","author":"Favaloro","year":"2024","journal-title":"Int. J. Lab. Hematol."},{"issue":"1","key":"10.1016\/j.thromres.2026.109795_bb0070","doi-asserted-by":"crossref","first-page":"14639","DOI":"10.1038\/s41598-021-93372-9","article-title":"Apixaban concentration variation and relation to clinical outcomes in real-life patients with atrial fibrillation","volume":"11","author":"Mavri","year":"2021","journal-title":"Sci. Rep."},{"issue":"10","key":"10.1016\/j.thromres.2026.109795_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtha.2024.07.009","article-title":"Reversal of direct oral anticoagulants: guidance from the SSC of the ISTH","volume":"22","author":"Levy","year":"2024","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2026.109795_bb0080","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1177\/23969873241310359","article-title":"Rapid assessment of direct oral anticoagulants in acute stroke\u2014an educational systematic review","volume":"10","author":"Mbroh","year":"2024","journal-title":"Eur. Stroke J."},{"issue":"1","key":"10.1016\/j.thromres.2026.109795_bb0085","first-page":"32","article-title":"Interlaboratory validation of apixaban levels in ex vivo patient samples using a chromogenic anti-factor Xa assay","volume":"42","author":"Singh","year":"2019"}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384826002148?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384826002148?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T16:28:35Z","timestamp":1787675315000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384826002148"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":17,"alternative-id":["S0049384826002148"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2026.109795","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term analytical performance of apixaban measurements based on external quality assessment data","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2026.109795","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"109795"}}